Developer docs
API playgroundTry for free, no card

Search company profiles

AIxMed

Full company profile

uuid0000ak6

Namestring
AIxMed
Legal namestring
AIxMed, Inc.
Websiteurl
aixmed.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

AIxMed, Inc. is a Santa Clara, Delaware-incorporated, venture-backed private company founded in 2018 by Samuel Chen and Dr. Tien-Jen Liu to apply machine learning and computer vision to cancer cytology. Its core product, AIxURO, is an FDA-designated Research Use Only software platform that analyzes whole slide images (WSI) of urine cytology specimens to identify suspicious and atypical urothelial cells using The Paris System (TPS 2.0) criteria, generating quantitative outputs such as N/C ratios, nuclear area, and ranked top-24 cell galleries. The platform is differentiated by proprietary multi-plane Z-stacking scanning and heuristic scanning algorithms that capture abnormal cells at all depths in 3D cytology samples while reducing scan time and file size versus conventional Z-stacking.

The company is extending this architecture across a four-product portfolio: AIxURO (urine/bladder, commercially available as RUO), AIxTHY (thyroid, near-term RUO, Bethesda System), and AIxPAP (cervical) and AIxPUL (pulmonary), both in development. The platform integrates with multiple slide scanners (Hamamatsu, Leica Aperio, 3DHistech, Mikroscan, Huron), preparation methods (ThinPrep, SurePath, CytoRich, Cytospin), and laboratory information systems via an open API, with file format support for .tiff, .svs, and jpeg.

AIxMed generates revenue by licensing its AI software to pathology laboratories, healthcare systems, and reference labs, primarily through subscription or enterprise licensing bundled with channel partnerships. Distribution combines direct enterprise sales (demo/consultation model) with channel partners including Lumea (FDA-cleared digital pathology platform), PathNet, CorePlus, Superb Diagnostics, and Bioptická Laboratoř, plus an education partnership with the American Society for Cytology (ASCT). The company has raised approximately $11M+ across disclosed rounds in 2021-2023 and reports 11-50 employees.

Short descriptiontext

AIxMed is an AI-native digital cytology company that builds computer vision software (AIxURO, AIxTHY, AIxPAP, AIxPUL) to detect cancer cells in urine, thyroid, cervical, and pulmonary specimens for pathology laboratories, urology practices, and reference labs via direct enterprise sales and channel partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Clara, United States
HQ citystring
Santa Clara
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital cytology software, AI cancer detection, computational pathology, urine cytology analysis, bladder cancer diagnostics
Industry5 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI Digital Pathology Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1AI Software Platform Licensing
TypeSubscription Recurring
Description

AIxMed generates revenue through licensing its AI-powered computational cytology software platform (AIxURO, AIxTHY) to pathology laboratories and healthcare systems. The software is currently designated Research Use Only (RUO), with the company working toward FDA submission for clinical diagnostic use. Revenue model appears to follow SaaS/subscription licensing with integration into laboratory digital workflows.

aixmed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1AIxURO
Description

AI-powered software for urinary cytology targeting bladder cancer detection, using The Paris System (TPS) criteria.

aixmed.com
+3 more records
Core offering1 text field

AIxMed develops and sells AI-powered computational digital cytology software platforms that analyze whole slide images (WSI) to detect cancer cells. Its lead product, AIxURO, performs AI-assisted urine cytology analysis for bladder cancer detection using The Paris System (TPS 2.0) criteria, identifying suspicious and atypical urothelial cells with quantitative measurements. The portfolio also includes AIxTHY for thyroid cancer detection (FNAC analysis using the Bethesda System), with AIxPAP (cervical) and AIxPUL (lung) in development. The platform integrates with multiple slide scanners and Laboratory Information Systems via an open API.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 50-80% reduction in diagnostic review time
+6 more records
Product overview1 text field

AIxMed offers a suite of AI-powered computational digital cytology platforms for cancer detection across multiple tissue types. The product portfolio includes AIxURO (commercially available for Research Use Only) for urine cytology and bladder cancer detection, AIxTHY (in development) for thyroid cytology, AIxPAP (in development) for cervical cancer screening, and AIxPUL (in development) for pulmonary cytology and lung cancer detection. The platforms combine whole slide imaging, advanced computer vision algorithms, and quantitative metrics following established cytology reporting standards (The Paris System for urine cytology, The Bethesda System for thyroid cytology) to assist pathologists in identifying abnormal cells, improving diagnostic accuracy, and enhancing workflow efficiency. All current products are designated For Research Use Only (RUO), not for use in diagnostic procedures.

Product and service4 records
1AIxURO
CategoryAI Cytology Software
Description

AI-powered digital cytology software for urine cytology analysis targeting bladder cancer detection. Uses The Paris System (TPS 2.0) criteria to identify suspicious (SHGUC/HGUC) and atypical (AUC) urothelial cells, providing quantitative statistics including N/C ratios and nuclear areas in a gallery view for pathologist review. Reduces diagnostic review time by 50-80% and achieves up to 93.7% concordance with manual microscopy in validation studies. Currently designated Research Use Only (RUO).

2AIxTHY
CategoryAI Cytology Software
Description

AI-powered digital cytology software for thyroid cancer diagnosis. Analyzes fine needle aspiration cytology (FNAC) samples using the Bethesda System (TBSRTC) to identify suspicious cells, classify nodules by cell type (follicular, oncocytic, histiocytes, lymphocytes, colloid), and distinguish benign from malignant nodules with quantitative scoring.

3AIxPAP
CategoryAI Cytology Software
Description

AI-powered digital cytology solution for cervical cancer detection, currently in development. Will analyze cervical cytology specimens to improve cancer diagnosis using established screening standards.

4AIxPUL
CategoryAI Cytology Software
Description

AI-powered digital cytology solution for pulmonary cytology and lung cancer detection, currently in development. Intended to empower precision in lung cancer detection.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Superb Diagnostics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-20
Description

Superb Dx and AIxMed announced reference lab service collaboration to integrate AIxMed's AIxURO technology into Superb Dx's digital pathology platform for urine cytology analysis. AI solution identifies suspicious and atypical cells using The Paris System (TPS 2.0) standards to improve accuracy and workflow efficiency in urothelial cell assessment for the urology market. AIxURO is currently designated as Research Use Only.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

CorePlus, a healthcare technology company based in San Juan, Puerto Rico, implemented AIxURO to enhance bladder cancer detection through improved urine cytology analysis. The platform analyzes whole slide images and presents abnormal cells following The Paris System diagnostic standards, reducing diagnostic review time by 50-80% while maintaining consistent accuracy. Technology aims to improve patient outcomes through earlier detection and reduced reliance on invasive cystoscopy.

3American Society for Cytology (ASCT)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

AIxMed and ASCT partnered to enhance cytology training with AIxMed's AIxURO software. Collaboration aims to integrate AI technology into educational workflows to advance diagnostic accuracy and efficiency. AIxURO analyzes urine cytology specimens to improve bladder cancer diagnosis.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

AIxMed and PathNet announced strategic partnership to enhance digital pathology services with AIxURO for improving bladder cancer diagnostics and workflow efficiency. Collaboration focuses on integrating AI-powered urine cytology analysis to support clinical decision-making and reduce invasive procedures.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

AIxMed and Bioptická Laboratoř announced strategic collaboration to advance AI-powered cytology in Europe. European implementation resulted in 30-50% faster workflow speed, improved sensitivity, and objective data for atypical cases.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-30
Description

AIxMed and Lumea partnered to integrate AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-native digital pathology company applying deep learning to whole-slide images for cancer detection across multiple tissue types. Directly comparable in applying computer vision to WSI for diagnostic decision support, though Paige is more advanced in prostate and broader oncology indications.

TypeDirect peer
Description

AI-powered cancer diagnostics for pathology, with deployed clinical products for breast, prostate, and gastric biopsy detection. Closely comparable as an AI pathology vendor selling into reference labs and health systems with FDA/CE-cleared products.

TypeDirect peer
Description

AI platform for pathology with both diagnostic products and pharma research offerings. Comparable as a direct AI-pathology competitor serving labs and biopharma, with overlapping WSI computer-vision technology.

TypeBroad incumbent
Description

FDA-cleared digital pathology platform integrating AIxURO for the U.S. urology market. Comparable as a broader digital pathology platform that bundles AIxMed's AI, and a partner/channel rather than pure competitor in the cytology niche.

TypeBroad incumbent
Description

Operates the widely deployed uPath/VENTANA digital pathology platform with scanners, image management, and AI partnerships. Comparable as a large incumbent whose installed base and scanner ecosystem could bundle competing AI cytology capabilities.

TypeBroad incumbent
Description

Maker of ThinPrep liquid-based cytology preparation, the dominant platform in non-gyn cytology and integrated with AIxMed. Comparable as a broad incumbent that controls upstream cytology prep and could internalize or bundle cytology AI.

TypeBroad incumbent
Description

Owns Aperio digital pathology scanners and staining platforms used in many of the same labs AIxMed targets. Comparable as a broad incumbent across the pathology workflow whose scanner franchise is a key integration point for AIxMed.

TypeBroad incumbent
Description

Manufacturer of NanoZoomer whole-slide scanners — one of the scanners AIxMed integrates with. Comparable as an incumbent WSI scanner vendor whose hardware ecosystem underpins cytology AI workflows.

TypeEmerging player
Description

Diagnostics company developing blood-based and other cancer-detection tests including for colorectal and other cancers. Comparable as an emerging player in cancer diagnostics but with a different specimen type (blood/serum vs. cytology).

TypeEmerging player
Description

AI pathology company focused on image-analysis workflows for diagnostic and pharma use. Comparable as a niche/emerging AI-pathology vendor with overlapping computer-vision approach and target labs, though smaller menu than AIxMed.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration13 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AIxMed

AI Digital Pathology Softwareaixmed.com

AIxMed is an AI-native digital cytology company that builds computer vision software (AIxURO, AIxTHY, AIxPAP, AIxPUL) to detect cancer cells in urine, thyroid, cervical, and pulmonary specimens for pathology laboratories, urology practices, and reference labs via direct enterprise sales and channel partners.

What AIxMed does

AIxMed, Inc. is a Santa Clara, Delaware-incorporated, venture-backed private company founded in 2018 by Samuel Chen and Dr. Tien-Jen Liu to apply machine learning and computer vision to cancer cytology. Its core product, AIxURO, is an FDA-designated Research Use Only software platform that analyzes whole slide images (WSI) of urine cytology specimens to identify suspicious and atypical urothelial cells using The Paris System (TPS 2.0) criteria, generating quantitative outputs such as N/C ratios, nuclear area, and ranked top-24 cell galleries. The platform is differentiated by proprietary multi-plane Z-stacking scanning and heuristic scanning algorithms that capture abnormal cells at all depths in 3D cytology samples while reducing scan time and file size versus conventional Z-stacking.

The company is extending this architecture across a four-product portfolio: AIxURO (urine/bladder, commercially available as RUO), AIxTHY (thyroid, near-term RUO, Bethesda System), and AIxPAP (cervical) and AIxPUL (pulmonary), both in development. The platform integrates with multiple slide scanners (Hamamatsu, Leica Aperio, 3DHistech, Mikroscan, Huron), preparation methods (ThinPrep, SurePath, CytoRich, Cytospin), and laboratory information systems via an open API, with file format support for .tiff, .svs, and jpeg.

AIxMed generates revenue by licensing its AI software to pathology laboratories, healthcare systems, and reference labs, primarily through subscription or enterprise licensing bundled with channel partnerships. Distribution combines direct enterprise sales (demo/consultation model) with channel partners including Lumea (FDA-cleared digital pathology platform), PathNet, CorePlus, Superb Diagnostics, and Bioptická Laboratoř, plus an education partnership with the American Society for Cytology (ASCT). The company has raised approximately $11M+ across disclosed rounds in 2021-2023 and reports 11-50 employees.

AIxMed firmographics

Firmographics
Name
AIxMed
Legal name
AIxMed, Inc.
Website
https://aixmed.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
AIxMed is an AI-native digital cytology company that builds computer vision software (AIxURO, AIxTHY, AIxPAP, AIxPUL) to detect cancer cells in urine, thyroid, cervical, and pulmonary specimens for pathology laboratories, urology practices, and reference labs via direct enterprise sales and channel partners.
Ownership category
akta.pro rank

AIxMed industry classification

Industry
Product category
AI Digital Pathology Software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Digital cytology software
  • AI cancer detection
  • Computational pathology
  • Urine cytology analysis
  • Bladder cancer diagnostics

Where AIxMed is headquartered

Location

Headquarters

HQ city
Santa Clara
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AIxMed business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. AI Software Platform Licensing: AIxMed generates revenue through licensing its AI-powered computational cytology software platform (AIxURO, AIxTHY) to pathology laboratories and healthcare systems. The software is currently designated Research Use Only (RUO), with the company working toward FDA submission for clinical diagnostic use. Revenue model appears to follow SaaS/subscription licensing with integration into laboratory digital workflows.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

AIxMed product offering

Product offering

Core offering

AIxMed develops and sells AI-powered computational digital cytology software platforms that analyze whole slide images (WSI) to detect cancer cells. Its lead product, AIxURO, performs AI-assisted urine cytology analysis for bladder cancer detection using The Paris System (TPS 2.0) criteria, identifying suspicious and atypical urothelial cells with quantitative measurements. The portfolio also includes AIxTHY for thyroid cancer detection (FNAC analysis using the Bethesda System), with AIxPAP (cervical) and AIxPUL (lung) in development. The platform integrates with multiple slide scanners and Laboratory Information Systems via an open API.

Product overview

AIxMed offers a suite of AI-powered computational digital cytology platforms for cancer detection across multiple tissue types. The product portfolio includes AIxURO (commercially available for Research Use Only) for urine cytology and bladder cancer detection, AIxTHY (in development) for thyroid cytology, AIxPAP (in development) for cervical cancer screening, and AIxPUL (in development) for pulmonary cytology and lung cancer detection. The platforms combine whole slide imaging, advanced computer vision algorithms, and quantitative metrics following established cytology reporting standards (The Paris System for urine cytology, The Bethesda System for thyroid cytology) to assist pathologists in identifying abnormal cells, improving diagnostic accuracy, and enhancing workflow efficiency. All current products are designated For Research Use Only (RUO), not for use in diagnostic procedures.

Differentiator

Problem solved

Functional benefit

Brands

  • AIxURO: AI-powered software for urinary cytology targeting bladder cancer detection, using The Paris System (TPS) criteria.
  • AIxTHY
  • AIxPAP
  • AIxPUL

Products and services

  • AIxURO AI-powered digital cytology software for urine cytology analysis targeting bladder cancer detection. Uses The Paris System (TPS 2.0) criteria to identify suspicious (SHGUC/HGUC) and atypical (AUC) urothelial cells, providing quantitative statistics including N/C ratios and nuclear areas in a gallery view for pathologist review. Reduces diagnostic review time by 50-80% and achieves up to 93.7% concordance with manual microscopy in validation studies. Currently designated Research Use Only (RUO).
  • AIxTHY AI-powered digital cytology software for thyroid cancer diagnosis. Analyzes fine needle aspiration cytology (FNAC) samples using the Bethesda System (TBSRTC) to identify suspicious cells, classify nodules by cell type (follicular, oncocytic, histiocytes, lymphocytes, colloid), and distinguish benign from malignant nodules with quantitative scoring.
  • AIxPAP AI-powered digital cytology solution for cervical cancer detection, currently in development. Will analyze cervical cytology specimens to improve cancer diagnosis using established screening standards.
  • AIxPUL AI-powered digital cytology solution for pulmonary cytology and lung cancer detection, currently in development. Intended to empower precision in lung cancer detection.

Quantifiable outcome

  • 50-80% reduction in diagnostic review time
  • +6 more outcomes

Companies that use AIxMed

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

AIxMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability5 records

Feature5 records

AIxMed partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Superb DiagnosticsminorStrategic or Co-development Partner · 20 March 2026Superb Dx and AIxMed announced reference lab service collaboration to integrate AIxMed's AIxURO technology into Superb Dx's digital pathology platform for urine cytology analysis. AI solution identifies suspicious and atypical cells using The Paris System (TPS 2.0) standards to improve accuracy and workflow efficiency in urothelial cell assessment for the urology market. AIxURO is currently designated as Research Use Only.
  • CorePluscoreStrategic or Co-development Partner · 7 January 2026CorePlus, a healthcare technology company based in San Juan, Puerto Rico, implemented AIxURO to enhance bladder cancer detection through improved urine cytology analysis. The platform analyzes whole slide images and presents abnormal cells following The Paris System diagnostic standards, reducing diagnostic review time by 50-80% while maintaining consistent accuracy. Technology aims to improve patient outcomes through earlier detection and reduced reliance on invasive cystoscopy.
  • American Society for Cytology (ASCT)minorStrategic or Co-development Partner · 17 November 2025AIxMed and ASCT partnered to enhance cytology training with AIxMed's AIxURO software. Collaboration aims to integrate AI technology into educational workflows to advance diagnostic accuracy and efficiency. AIxURO analyzes urine cytology specimens to improve bladder cancer diagnosis.
  • PathNetcoreStrategic or Co-development Partner · 3 November 2025AIxMed and PathNet announced strategic partnership to enhance digital pathology services with AIxURO for improving bladder cancer diagnostics and workflow efficiency. Collaboration focuses on integrating AI-powered urine cytology analysis to support clinical decision-making and reduce invasive procedures.
  • Bioptická LaboratořminorStrategic or Co-development Partner · 1 October 2025AIxMed and Bioptická Laboratoř announced strategic collaboration to advance AI-powered cytology in Europe. European implementation resulted in 30-50% faster workflow speed, improved sensitivity, and objective data for atypical cases.
  • LumeacoreChannel Partner/ Reseller/ Distributor · 30 May 2025AIxMed and Lumea partnered to integrate AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

AIxMed competitors and assessment

Company assessment

Direct peers

  • Paige.AI: AI-native digital pathology company applying deep learning to whole-slide images for cancer detection across multiple tissue types. Directly comparable in applying computer vision to WSI for diagnostic decision support, though Paige is more advanced in prostate and broader oncology indications.
  • Ibex Medical Analytics: AI-powered cancer diagnostics for pathology, with deployed clinical products for breast, prostate, and gastric biopsy detection. Closely comparable as an AI pathology vendor selling into reference labs and health systems with FDA/CE-cleared products.
  • PathAI: AI platform for pathology with both diagnostic products and pharma research offerings. Comparable as a direct AI-pathology competitor serving labs and biopharma, with overlapping WSI computer-vision technology.

Broad incumbents

  • Lumea: FDA-cleared digital pathology platform integrating AIxURO for the U.S. urology market. Comparable as a broader digital pathology platform that bundles AIxMed's AI, and a partner/channel rather than pure competitor in the cytology niche.
  • Roche Digital Pathology: Operates the widely deployed uPath/VENTANA digital pathology platform with scanners, image management, and AI partnerships. Comparable as a large incumbent whose installed base and scanner ecosystem could bundle competing AI cytology capabilities.
  • Hologic: Maker of ThinPrep liquid-based cytology preparation, the dominant platform in non-gyn cytology and integrated with AIxMed. Comparable as a broad incumbent that controls upstream cytology prep and could internalize or bundle cytology AI.
  • Danaher / Leica Biosystems: Owns Aperio digital pathology scanners and staining platforms used in many of the same labs AIxMed targets. Comparable as a broad incumbent across the pathology workflow whose scanner franchise is a key integration point for AIxMed.
  • Hamamatsu Photonics: Manufacturer of NanoZoomer whole-slide scanners — one of the scanners AIxMed integrates with. Comparable as an incumbent WSI scanner vendor whose hardware ecosystem underpins cytology AI workflows.

Emerging players

  • VolitionRx: Diagnostics company developing blood-based and other cancer-detection tests including for colorectal and other cancers. Comparable as an emerging player in cancer diagnostics but with a different specimen type (blood/serum vs. cytology).
  • Mindpeak: AI pathology company focused on image-analysis workflows for diagnostic and pharma use. Comparable as a niche/emerging AI-pathology vendor with overlapping computer-vision approach and target labs, though smaller menu than AIxMed.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

AIxMed social profiles

Digital presence

AIxMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AIxMed leadership team

Management profile

Number of profiles

Profiles4 records

AIxMed funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AIxMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIxMed

What does AIxMed do?

AIxMed develops and sells AI-powered computational digital cytology software platforms that analyze whole slide images (WSI) to detect cancer cells. Its lead product, AIxURO, performs AI-assisted urine cytology analysis for bladder cancer detection using The Paris System (TPS 2.0) criteria, identifying suspicious and atypical urothelial cells with quantitative measurements. The portfolio also includes AIxTHY for thyroid cancer detection (FNAC analysis using the Bethesda System), with AIxPAP (cervical) and AIxPUL (lung) in development. The platform integrates with multiple slide scanners and Laboratory Information Systems via an open API.

Is AIxMed a public or private company?

AIxMed is a private company. It is classified as venture growth investor backed and is currently operating.

When was AIxMed founded?

AIxMed was founded in 2018. It employs 11 to 50 people.

Where is AIxMed based?

AIxMed is headquartered in Santa Clara, United States, in the North America region.

How does AIxMed make money?

One revenue line is on record: AI Software Platform Licensing.

Who are AIxMed's main competitors?

Direct peers on record are Paige.AI, Ibex Medical Analytics and PathAI. Broad incumbents are Lumea, Roche Digital Pathology, Hologic, Danaher / Leica Biosystems and Hamamatsu Photonics. Emerging players are VolitionRx and Mindpeak.

Does AIxMed have an API?

No public API is recorded for AIxMed.

What industry is AIxMed in?

AIxMed's product category is AI Digital Pathology Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournHamamatsu and AIxMed Announce Collaboration to Evaluate ScanPilot Integration in Cytology Research WorkflowsHamamatsu and AIxMed announced a collaboration to evaluate ScanPilot integration with NanoZoomer scanners for cytology research workflows. ScanPilot analyzes digitized slide images for image quality and proposes rescanning parameters. The partnership aims to automate manual quality checks and focus-point placement in cytology digitization.PR NewswireHamamatsu and AIxMed Announce Collaboration to Evaluate ScanPilot Integration in Cytology Research WorkflowsHamamatsu and AIxMed announced a collaboration to evaluate ScanPilot integration with NanoZoomer scanners for cytology workflows. ScanPilot assesses image quality and proposes rescanning parameters for compatible configurations. The partnership aims to automate manual quality checks and focus-point placement in cytology digitization.EIN PresswireSuperb Diagnostics to Launch Digital Urine Cytology Service with AI-Powered Image AnalysisSuperb Dx and AIxMed announced a new reference lab service collaboration to integrate AIxMed's AIxURO technology into Superb Dx's digital pathology platform for urine cytology analysis. The AI solution identifies suspicious and atypical cells from urine samples using The Paris System (TPS 2.0) standards and is designed to improve accuracy and workflow efficiency in urothelial cell assessment for the urology market. AIxURO is currently designated as Research Use Only, with the partnership expanding Superb Dx's diagnostic offerings for urologists, oncologists, and researchers.PR NewswireAIxMed and PathNet Partnership: Advancing Digital Pathology with AI-Powered Urine CytologyAIxMed and PathNet announced a partnership to integrate AIxMed's AIxURO urine cytology software into PathNet's digital pathology platform. The software uses The Paris System for Reporting Urinary Cytology to identify suspicious cells, aiming to improve diagnostic accuracy and reduce invasive procedures like cystoscopies.DIGITIMES AsiaPathologist shortage spurs AIxMed's push toward AI-assisted diagnosisAIxMed, co-founded by Samuel Chen, develops AI tools for cytological slide analysis to address a global pathologist shortage. A 2016 study cited shows AI-assisted interpretation reduces error rates to 0.5% from 3.5% for manual work. The company plans to expand from image analysis to AI agents for diagnostic reporting.Clinical Lab ProductsPartnership Enhances Digital Pathology Platform with AI-Powered Urine Cytology SolutionAIxMed and Lumea have partnered to integrate AIxMed's AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive procedures like cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem serving a significant portion of the U.S. urology market.PR NewswireAIxMed Partnership with Lumea Enhances Digital Pathology Platform with AI-Powered Urine Cytology SolutionAIxMed and Lumea announced a partnership to integrate AIxMed's AIxURO urine cytology technology into Lumea's FDA-cleared digital pathology platform, targeting improved bladder cancer diagnostics. The solution will assist in analyzing non-invasive urine cytology specimens using The Paris System for Reporting Urinary Cytology, with the goal of reducing the need for invasive cystoscopy procedures. Lumea will add this capability to its digital pathology ecosystem, which serves a significant portion of the U.S. urology market.PR NewswireAIxMed and CorePlus Partner to study a Urine Cytology Workflow SolutionAIxMed and CorePlus have entered into an agreement to conduct a pilot study applying AIxMed's AI algorithm to test a workflow solution for urine cytology analysis. The partnership combines AIxMed's computational cytology platform with CorePlus's digital pathology integration capabilities to address the shortage of cytologists and the manual nature of cell characterization. Both companies aim to deliver an end-to-end solution for research-use only urine cytology analysis that could improve accuracy and efficiency in bladder cancer research.PR NewswireAIxMed Welcomes Barbara Crothers, D.O., as Chief Scientist and Appoints Two Scientific AdvisorsAIxMed, an early-stage smart Cytology company combining AI and medicine, announced the appointment of Barbara Crothers, D.O. as Chief Scientist to lead U.S.-based pilot and validation studies for its CytoInsights digital Cytology platform targeting bladder cancer diagnosis. The company also appointed two scientific advisors — Dr. Liron Pantanowitz and Dr. Christopher VandenBussche — to support its pathology market penetration and platform commercialization efforts. Dr. Crothers brings over thirty years of industry expertise, including prior service as Senior Pathologist at the Joint Pathology Center and leadership roles in professional organizations including the American Society of Cytopathology.VC News DailyAIxMed Lands $2.75MAIxMed announced that it has raised $2.75 million in a SAFE round of financing from existing investors in Santa Clara, CA. The funds will be used to further develop its digital cytology platform, including their AI-assisted urine cytology imaging and reporting software, AIxURO, for bladder cancer diagnosis. This financing positions AIxMed to enhance the speed and accuracy of patient diagnosis and care.